On Friday, Human Genome Sciences told GlaxoSmithKline that it should submit a “final bid” for HGS by July 16. GSK is making a tender offer directly to HGS shareholders to buy HGS for $13 per share. HGS has rejected that bid as too low and has vowed to seek alternatives.
- GlaxoSmithKline Eyes Replacing Human Genome Sciences, Inc. Board (biospace.com)
- Human Genome Sciences Announces July 16 As The Date For Submission Of Definitive Acquisition Proposals (bioresearchonline.com)
- Glaxo Extends Deadline for Human Genome Sciences Bid (dealbook.nytimes.com)